Filed Pursuant to Rule 424(b)(3)
Registration No. 333-273395
Prospectus Supplement
(to prospectus dated October 27, 2023)
82,696,181 Shares
COMMON STOCK
Offered by the Selling Stockholders
On October 27, 2023, Gyre Therapeutics, Inc. (formerly known as Catalyst Biosciences, Inc., the “Company”) filed a prospectus (the “Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to the potential resale from time to time by the Selling Stockholders (as defined below) of up to a certain number of shares of common stock, par value $0.001 per share (“Common Stock”), of the Company.
On October 30, 2023, the Company consummated the previously announced business combination (the “Closing”) pursuant to that certain Business Combination Agreement (as defined below). Pursuant to the terms of the Business Combination Agreement, at the Closing, the Company acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People’s Republic of China.
On October 30, 2023 and in connection with the Closing, the Company, among other things, effected a 1-for-15 reverse stock split of Common Stock (the “Reverse Stock Split”).
The Company is furnishing this supplement (this “supplement”) to update and supplement information contained in the Prospectus to account for the occurrence of the Closing and to decrease the number of the Resale Shares by giving effect to the Reverse Stock Split.
This supplement is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This supplement should be read in conjunction with the Prospectus and any prior amendments or supplements thereto and if there is any inconsistency between the information therein and this supplement, you should rely on the information in this supplement.
Capitalized terms used and not defined in this supplement have the meanings set forth in the Prospectus.
Our Common Stock is currently listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “GYRE.”
On October 31, 2023, the last reported sale price of our Common Stock as reported on Nasdaq was $6.93 per share.
Investing in our Common Stock involves risk. See “Risk Factors” beginning on page 11 of the Prospectus and in the documents incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.
The SEC and state securities regulators have not approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is November 1, 2023.